UA97348C2 - HETEROCYCLIC NF-kB INHIBITORS - Google Patents
HETEROCYCLIC NF-kB INHIBITORSInfo
- Publication number
- UA97348C2 UA97348C2 UAA200802635A UAA200802635A UA97348C2 UA 97348 C2 UA97348 C2 UA 97348C2 UA A200802635 A UAA200802635 A UA A200802635A UA A200802635 A UAA200802635 A UA A200802635A UA 97348 C2 UA97348 C2 UA 97348C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heterocyclic
- inhibitors
- hyperproliferation
- stereoisomer
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Abstract
The present invention relates to compound of the general formula (Ih)or pharmaceutically acceptable salt thereof with an acid or a base, or a stereoisomer thereof, which are used the preparation of medicament for the treatment and/or prevention of diseases characterized by hyperproliferation of cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2005/008261 WO2006032322A1 (en) | 2004-09-20 | 2005-07-29 | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
PCT/EP2006/002396 WO2007016979A2 (en) | 2005-07-29 | 2006-03-15 | NOVEL HETEROCYCLIC NF-κB INHIBITORS |
Publications (1)
Publication Number | Publication Date |
---|---|
UA97348C2 true UA97348C2 (en) | 2012-02-10 |
Family
ID=36570358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200802635A UA97348C2 (en) | 2005-07-29 | 2006-03-15 | HETEROCYCLIC NF-kB INHIBITORS |
Country Status (13)
Country | Link |
---|---|
JP (1) | JP2009502816A (en) |
KR (1) | KR20080031038A (en) |
CN (1) | CN101233119A (en) |
AU (1) | AU2006278998A1 (en) |
BR (1) | BRPI0614188A2 (en) |
CA (1) | CA2617225A1 (en) |
EA (1) | EA016300B1 (en) |
IL (1) | IL189112A0 (en) |
NO (1) | NO20081056L (en) |
NZ (2) | NZ588971A (en) |
SG (1) | SG172738A1 (en) |
UA (1) | UA97348C2 (en) |
WO (1) | WO2007016979A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA012607B1 (en) * | 2004-09-20 | 2009-10-30 | 4Сц Аг | NOVEL HETEROCYCLIC NF-kB INHIBITORS |
JP2009529555A (en) * | 2006-03-15 | 2009-08-20 | 4エスツェー アクチェンゲゼルシャフト | Novel heterocyclic NF-κB inhibitor |
WO2009037357A1 (en) * | 2007-09-19 | 2009-03-26 | 4Sc Ag | Benzimidazole nf- kappab inhibitors |
SI2805720T1 (en) | 2008-05-28 | 2019-11-29 | Reveragen Biopharma Inc | Non-hormonal steroid modulators of NF-KB for treatment of disease |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
PT2959900T (en) * | 2008-06-16 | 2017-06-22 | Univ Tennessee Res Found | Compound for treatment of cancer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
CN102883607B (en) | 2010-03-01 | 2015-07-22 | Gtx公司 | Compounds for treatment of cancer |
US10464967B2 (en) | 2011-11-29 | 2019-11-05 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κβ for treatment of disease |
US10005769B2 (en) * | 2013-06-18 | 2018-06-26 | 4Sc Ag | 2,3-dihydrobenzofuran-5YL compounds as DYRK kinase inhibitors |
SI3099684T1 (en) * | 2014-01-29 | 2018-08-31 | Ucb Biopharma Sprl | Heteroaryl amides as inhibitors of protein aggregation |
US10799514B2 (en) | 2015-06-29 | 2020-10-13 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-kappa beta for treatment of disease |
US11382922B2 (en) | 2019-03-07 | 2022-07-12 | Reveragen Biopharma, Inc. | Aqueous oral pharmaceutical suspension compositions |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW263508B (en) * | 1991-02-12 | 1995-11-21 | Pfizer | |
DK0870765T3 (en) * | 1995-05-18 | 2004-02-23 | Zeria Pharm Co Ltd | Aminothiazole derivative, drug containing the same and intermediate for the preparation of the compound |
JPH0987282A (en) * | 1995-09-21 | 1997-03-31 | Kyowa Hakko Kogyo Co Ltd | Thiazole derivative |
WO1997012613A1 (en) * | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
DE19817459A1 (en) * | 1998-04-20 | 1999-10-21 | Basf Ag | New heterocyclic amide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc. |
WO1999062885A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
DE19858593A1 (en) * | 1998-12-18 | 2000-06-21 | Merck Patent Gmbh | (2-Phenyl-4-(phenylsulfonyl)-oxazol-5-yl)-amine therapeutic agents having 5-HT6 receptor affinity, useful for treating CNS disorders such as psychosis, schizophrenia, depression or Alzheimer's disease |
ES2259617T3 (en) * | 1999-11-05 | 2006-10-16 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) | HETEROCICLICAL COMPOUNDS AND ITS APPLICATION AS MEDICINES. |
WO2002064558A2 (en) * | 2001-02-14 | 2002-08-22 | Sankyo Company, Limited | Oxazole derivatives, their preparation and their use as cytokine inhibitors |
WO2003027100A1 (en) * | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | Substituted 3-pyridyl pyrimidines as c17,20 lyase inhibitors |
GB0130868D0 (en) * | 2001-12-24 | 2002-02-06 | Univ Strathclyde | New compounds |
JP2005525309A (en) * | 2002-01-10 | 2005-08-25 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | The combination of MTP inhibitors or apoB secretion inhibitor and fibrate for use as a medicament |
RU2326881C9 (en) * | 2002-09-30 | 2009-04-10 | Байер Фармасьютикалс Корпорейшн | Condensed derivatives of azolpyrimine with inhibiting properties of phosphatidyl inositol-3-kinase (pi3k) |
GB0230162D0 (en) * | 2002-12-24 | 2003-02-05 | Metris Therapeutics Ltd | Compounds useful in inhibiting angiogenesis |
FR2856685B1 (en) * | 2003-06-25 | 2005-09-23 | Merck Sante Sas | THIAZOLYLPIPERIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US20050090529A1 (en) * | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
WO2005030206A1 (en) * | 2003-09-24 | 2005-04-07 | Imclone Systems Incorporated | Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity |
WO2005079791A1 (en) * | 2004-02-12 | 2005-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders |
US20070293482A1 (en) * | 2004-03-19 | 2007-12-20 | Novartis Pharmaceuticals Corporation | Process for Preparing Benzodiazepines |
EA012607B1 (en) * | 2004-09-20 | 2009-10-30 | 4Сц Аг | NOVEL HETEROCYCLIC NF-kB INHIBITORS |
-
2006
- 2006-03-15 NZ NZ588971A patent/NZ588971A/en not_active IP Right Cessation
- 2006-03-15 CA CA002617225A patent/CA2617225A1/en not_active Abandoned
- 2006-03-15 SG SG2011047610A patent/SG172738A1/en unknown
- 2006-03-15 KR KR1020087002431A patent/KR20080031038A/en not_active Application Discontinuation
- 2006-03-15 NZ NZ565470A patent/NZ565470A/en not_active IP Right Cessation
- 2006-03-15 CN CNA2006800272993A patent/CN101233119A/en active Pending
- 2006-03-15 WO PCT/EP2006/002396 patent/WO2007016979A2/en active Application Filing
- 2006-03-15 UA UAA200802635A patent/UA97348C2/en unknown
- 2006-03-15 EA EA200800175A patent/EA016300B1/en not_active IP Right Cessation
- 2006-03-15 BR BRPI0614188-9A patent/BRPI0614188A2/en not_active IP Right Cessation
- 2006-03-15 JP JP2008523136A patent/JP2009502816A/en active Pending
- 2006-03-15 AU AU2006278998A patent/AU2006278998A1/en not_active Abandoned
-
2008
- 2008-01-29 IL IL189112A patent/IL189112A0/en unknown
- 2008-02-28 NO NO20081056A patent/NO20081056L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20080031038A (en) | 2008-04-07 |
AU2006278998A1 (en) | 2007-02-15 |
CA2617225A1 (en) | 2007-02-15 |
IL189112A0 (en) | 2008-08-07 |
BRPI0614188A2 (en) | 2011-03-15 |
EA016300B1 (en) | 2012-04-30 |
WO2007016979A3 (en) | 2007-08-02 |
SG172738A1 (en) | 2011-07-28 |
NO20081056L (en) | 2008-02-28 |
WO2007016979A2 (en) | 2007-02-15 |
NZ588971A (en) | 2012-06-29 |
NZ565470A (en) | 2010-11-26 |
EA200800175A1 (en) | 2008-08-29 |
JP2009502816A (en) | 2009-01-29 |
CN101233119A (en) | 2008-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
TW200728307A (en) | Novel spirochromanone derivatives | |
TW200833663A (en) | Therapeutic agents | |
TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
WO2005075425A3 (en) | Substituted bisarylurea derivatives as kinase inhibitors | |
WO2009155121A3 (en) | Inhibitors of pi3 kinase | |
MX2007010532A (en) | 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus. | |
TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
JO2885B1 (en) | Protein kinase inhibitors | |
MX2009006742A (en) | Novel compounds. | |
TN2010000019A1 (en) | Solid preparation comprising alogliptin and metformin hydrochloride | |
IN2012DN03085A (en) | ||
MX2011012122A (en) | Thiophene derivatives. | |
TN2012000152A1 (en) | Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes | |
MX346186B (en) | Protein kinase inhibitors. | |
MY151295A (en) | Pyrimidyl indoline compound | |
MX2007013624A (en) | Protein kinase inhibitors. | |
TW200626158A (en) | Naphthaline derivatives | |
WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
UA105229C2 (en) | Pharmaceutical formulation | |
SE0400284D0 (en) | Novel compounds | |
IL193252A0 (en) | N-hydroxyacrylamide compounds | |
NO20083708L (en) | 4-Phenyl-thiazole-5-carboxylic acid and 4-phenyl-thiazole-5-carboxylmides as PLK1 inhibitors | |
TN2010000038A1 (en) | Organic compounds | |
EA201001747A1 (en) | BENZOXASINIC DERIVATIVES, ACTING AS AN AGONIST BETA-2-ADRENOCEPTOR, FOR THE TREATMENT OF RESPIRATORY DISORDERS |